FocusPolicy

Use Patents Can Be Useful: The Case of Rescued Drugs

See allHide authors and affiliations

Science Translational Medicine  06 Aug 2014:
Vol. 6, Issue 248, pp. 248fs30
DOI: 10.1126/scitranslmed.3009120

Tables

  • Table 1

    Patent information on selected NCATS molecules.

    Molecule codePatent no.Patent namePriority date*InventorsNotes
    LY500303077,354,951Substituted benzopyrans as selective estrogen receptor–β agonists5 October 2005Bryan Hurst Norman; Timothy Ivo Richardson
    7,442,812Substituted benzopyrans as selective estrogen receptor–β agonists8 April 2004Gregory Lee Durst; Bryan Hurst Norman; Timothy Ivo Richarson
    7,585,985Substituted benzopyrans as selective estrogen receptor–β agonists8 April 2004Bryan Hurst Norman; Lance Allen Pfeifer; Timothy Ivo RichardsonDivisional of ‘812 patent†
    7,842,822Substituted benzopyrans as selective estrogen receptor–β agonists8 April 2004Gregory Lee Durst; Bryan Hurst Norman; Timothy Ivo RichardsonDivisional of ‘812 patent†
    AZF0530(2 projects)8,304,417Crystalline forms of 4-(6-chloro-2, 3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl) ethoxy]-5-tetrahydropyran-4-yloxyquinazoline14 December 2005James Gair Ford et al.
    ZD40545,866,568Heterocyclic compounds4 June 1996Robert Hugh Bradbury et al.
    6,060,475Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof4 June 1996Robert Hugh Bradbury et al.Divisional of ‘568 patent†
    6,258,817Substituted pyrazin-2-yl-sulphonamide (-3-pyridyl) compounds and uses thereof4 June 1996Robert Hugh Bradbury et al.Divisional of ‘568 patent†
    PF-034632758,124,639Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors6 April 2006Stanton F. McHardy; John A. Lowe III

    *The priority date is the date from which the 20-year patent term begins. †A divisional is a patent that is a subset of, and thus has the same priority date as, a prior patent.

    Stay Connected to Science Translational Medicine

    Navigate This Article